Check your patient ’ s eligibility for Repatha ® using the simple PBS navigator at www . repatha . com . au
Passcode : PBS _ Tool
* 1 , 2
PREVENT ANOTHER CV EVENT * 1 , 2
* Repatha ® is indicated for the prevention of CV events ( MI , stroke and coronary revascularisation ) in adults with established CV disease in combination with an optimally dosed statin and / or other lipid-lowering therapies , as an adjunct to diet and exercise . 1
‘ Power ’: 15 % relative risk reduction with Repatha ® vs placebo in the composite of the primary endpoint beyond optimised statin ± ezetimibe ( HR : 0.85 ; 95 % CI : 0.79 – 0.92 , p < 0.001 ). 2
PBS Information : Authority Required . Non-familial and familial hypercholesterolaemia . Criteria apply for certain patient populations . Refer to PBS Schedule for full Authority Required Information .
Refer to full Product Information before prescribing ; available from Amgen Australia Pty Ltd , Ph : 1800 803 638 or by scanning the QR code : For more information on Repatha ® or to report an adverse event or product complaint involving Repatha ® , please contact Amgen Medical Information on 1800 803 638 or visit www . amgenmedinfo . com . au .
Precautions : Hypersensitivity reactions . Concomitant lipid lowering therapies – check all relevant prescribing information . Effects of long-term very low LDL-C levels are unknown . Immunogenic potential . Pregnancy Category : B1 . Caution – breastfeeding . Adverse Reactions : Common – nasopharyngitis , upper respiratory tract infection , influenza , back pain , arthralgia , nausea , rash , and injection site reactions ( including injection site pain , erythema , bruising , swelling or haemorrhage ).
Abbreviations : CI , confidence interval ; CV , cardiovascular ; HR , hazard ratio ; MI , myocardial infarction ; PBS , Pharmaceutical Benefits Scheme . References : 1 . Repatha ® ( evolocumab ) product information . 2 . Sabatine MS et al . N Engl J Med 2017 ; 376:1713 – 1722 .
Amgen Australia Pty Ltd . ABN 31 051 057 428 , Sydney NSW 2000 . © 2023 Amgen Inc . All rights reserved . AUS-145-0923-80013 . AMG8253 . Date of preparation : September 2023 .